Atomizer for thermal management system

An atomizer for thermal management system for efficiently thermally managing one or more heat producing devices. The atomizer for thermal management system includes a housing having a coolant passage and a dispensing end, an orifice within the dispensing end, and an actuator manipulating a plunger within the housing. The plunger includes a head that is sealable within a recessed portion of the orifice to open or close the orifice. The coolant passes through the coolant passage into the orifice for spraying upon a heat producing device. The actuator may reciprocate so that the coolant spray emitted through the orifice is pulsating. The pulsing frequency may be increased to increase cooling or decreased to decrease cooling of the heat producing device

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

HST-COS Observations Of AGNs. II. Extended Survey Of Ultraviolet Composite Spectra From 159 Active Galactic Nuclei

The ionizing fluxes from quasars and other active galactic nuclei (AGNs) are critical for interpreting their emissionline spectra and for photoionizing and heating the intergalactic medium. Using far-ultraviolet (FUV) spectra from the Cosmic Origins Spectrograph (COS) on the Hubble Space Telescope (HST), we directly measure the rest-frame ionizing continua and emission lines for 159 AGNs at redshifts 0.001 < Z(AGN) < 1.476 and construct a composite spectrum from 475 to 1875 A. We identify the underlying AGN continuum and strong extreme ultraviolet (EUV) emission lines from ions of oxygen, neon, and nitrogen after masking out absorption lines from the HI Ly alpha forest, 7 Lyman-limit systems (N-HI, 10(17.2) Cm-2) and 214 partial Lyman-limit systems (14.5 < log N-HI < 17.2). The 159 AGNs exhibit a wide range of FUV/EUV spectral shapes, F-V, proportional to v(proportional to v)(4, typically with -2 <= alpha(v), <= 0 and no discernible continuum edges at 912 angstrom (HI) or 504 angstrom (He I). The composite rest-frame continuum shows a gradual break at lambda(br) approximate to 1000 angstrom, with mean spectral index alpha(v) = -0.83 +/- 0.09 in the FUV (1200-2000 angstrom) steepening to alpha(v), = -1.41 +/- 0.15 in the EUV (500-1000 angstrom). We discuss the implications of the UV flux turnovers and lack of continuum edges for the structure of accretion disks, AGN mass inflow rates, and luminosities relative to Eddington values.NASA NNX08-AC14G, NAS5-98043Astrophysical Theory Program from NASA at the University of Colorado Boulder NNX07-AG77GSackler Visitor programAstronom

Early Neural and Vascular Dysfunctions in Diabetic Rats Are Largely Sequelae of Increased Sorbitol Oxidation

These experiments were undertaken to assess the importance of cytoplasmic (c) sorbitol oxidation versus mitochondrial (m) pyruvate oxidation in mediating neural and vascular dysfunction attributable to hyperglycemia in diabetic rats. Increased oxidation of sorbitol is coupled to enzymatic reduction of free oxidized NAD+c to reduced NADHc, manifested by an increased ratio of NADH to NAD+c. Likewise, increased oxidation of pyruvate is coupled to reduction of NAD+m to NADHm, which increases the NADH/NAD+m ratio. Specific inhibitors of sorbitol production or sorbitol oxidation normalized: increased diabetic nerve NADH/NAD+c, impaired nerve-conduction velocity, and vascular dysfunction in sciatic nerve, retina, and aorta; however, they had little or no impact on increased NADH/NAD+m. These observations provide, for the first time, strong in vivo evidence for the primacy of sorbitol oxidation versus. pyruvate oxidation in mediating the metabolic imbalances, impaired nerve conduction, and vascular dysfunction evoked by diabetes. These findings are consistent with (a) the fact that oxidation of sorbitol produces “prooxidant” NADHc uncoupled from subsequent production of “antioxidant” pyruvate required for reoxidation of NADHc to NAD+c by lactate dehydrogenase, and (b) the hypothesis that neural and vascular dysfunction in early diabetes are caused primarily by increased NADHc, which fuels superoxide production by NADH-driven oxidases. Antioxid. Redox Signal. 12, 39–51